Literature DB >> 17109469

The structure of the human allo-ligand HLA-B*3501 in complex with a cytochrome p450 peptide: steric hindrance influences TCR allo-recognition.

Christopher S Hourigan1, Maria Harkiolaki, Neil A Peterson, John I Bell, E Yvonne Jones, Chris A O'Callaghan.   

Abstract

Virus-specific T cell populations have been implicated in allo-recognition. The subdominant T cell receptor JL12 recognizes both HLA-B*0801 presenting the Epstein-Barr virus-derived peptide FLRGRAYGL and also HLA-B*3501 presenting the cytochrome p450 self peptide KPIVVLHGY. This cross-reactivity could promote the rejection of HLA-B*3501-positive cells in Epstein-Barr virus-exposed HLA-B*0801 recipients. LC13, the dominant TCR against the HLA-B*0801:FLRGRAYGL complex, fails to recognize HLA-B*3501:KPIVVLHGY. We report the 1.75-Angstrom resolution crystal structure of the human allo-ligand HLA-B*3501:KPIVVLHGY. Similarities between this structure and that of HLA-B*0801:FLRGRAYGL may facilitate cross-recognition by JL12. Moreover, the elevated peptide position in HLA-B*3501:KPIVVLHGY would provide steric hindrance to LC13, preventing it from interacting in the manner in which it interacts with HLA-B*0801:FLRGRAYGL. These findings are relevant to understanding the basis of T cell cross-reactivity in allo-recognition, optimal transplant donor-recipient matching and developing specific molecular inhibitors of allo-recognition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109469     DOI: 10.1002/eji.200636234

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.

Authors:  Tze Guan Tan; Ernest Mui; Hua Cong; William H Witola; Alexandre Montpetit; Stephen P Muench; John Sidney; Jeff Alexander; Alessandro Sette; Michael E Grigg; Ajesh Maewal; Rima McLeod
Journal:  Vaccine       Date:  2010-03-26       Impact factor: 3.641

2.  T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope.

Authors:  Angela Wahl; William McCoy; Fredda Schafer; Wilfried Bardet; Rico Buchli; Daved H Fremont; William H Hildebrand
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

3.  Peptide-dependent conformational fluctuation determines the stability of the human leukocyte antigen class I complex.

Authors:  Saeko Yanaka; Takamasa Ueno; Yi Shi; Jianxun Qi; George F Gao; Kouhei Tsumoto; Kenji Sugase
Journal:  J Biol Chem       Date:  2014-07-15       Impact factor: 5.157

4.  Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses.

Authors:  Stephanie Gras; Lukasz Kedzierski; Sophie A Valkenburg; Karen Laurie; Yu Chih Liu; Justin T Denholm; Michael J Richards; Guus F Rimmelzwaan; Anne Kelso; Peter C Doherty; Stephen J Turner; Jamie Rossjohn; Katherine Kedzierska
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

5.  Structural basis for T cell alloreactivity among three HLA-B14 and HLA-B27 antigens.

Authors:  Pravin Kumar; Ardeschir Vahedi-Faridi; Wolfram Saenger; Elena Merino; José A López de Castro; Barbara Uchanska-Ziegler; Andreas Ziegler
Journal:  J Biol Chem       Date:  2009-07-18       Impact factor: 5.157

6.  In-silico identification of the vaccine candidate epitopes against the Lassa virus hemorrhagic fever.

Authors:  Prabin Baral; Elumalai Pavadai; Bernard S Gerstman; Prem P Chapagain
Journal:  Sci Rep       Date:  2020-05-06       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.